Skip to main content

Annovis Bio, Inc.

corporate_fare Company Profile

Annovis Bio, Inc.

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's lead product candidate is Buntanetap, which is in phase 2/3 to treat alzheimer's disease, as well as in phase 3 to treat parkinson's disease; and is in phase 2 clinical trial to treat lewy body dementia. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial to treat later stages of alzheimer's disease and dementia. The company was incorporated in 2008 and is headquartered in Malvern, Pennsylvania.

Exchange: NYSESector: Life Sciences

show_chartPrice Chart

Loading chart...

feed ANVS - Latest Insights

ANVS
Apr 09, 2026, 5:50 PM EDT
Filing Type: 8-K
Importance Score:
9
ANVS
Apr 09, 2026, 5:09 PM EDT
Filing Type: 424B5
Importance Score:
9
ANVS
Apr 09, 2026, 8:30 AM EDT
Source: GlobeNewswire
Importance Score:
8
ANVS
Apr 03, 2026, 5:06 PM EDT
Filing Type: 4
Importance Score:
9
ANVS
Apr 02, 2026, 7:30 AM EDT
Source: GlobeNewswire
Importance Score:
7
ANVS
Mar 25, 2026, 5:19 PM EDT
Filing Type: 8-K
Importance Score:
7
ANVS
Mar 16, 2026, 5:06 PM EDT
Filing Type: 8-K
Importance Score:
7
ANVS
Mar 16, 2026, 7:30 AM EDT
Source: EQS
Importance Score:
8
ANVS
Mar 13, 2026, 5:15 PM EDT
Filing Type: 10-K
Importance Score:
9
ANVS
Feb 12, 2026, 9:00 AM EST
Filing Type: 8-K
Importance Score:
8
ANVS
Jan 28, 2026, 4:28 PM EST
Filing Type: 8-K
Importance Score:
7